{"id":36867,"date":"2025-12-12T18:12:41","date_gmt":"2025-12-12T23:12:41","guid":{"rendered":"https:\/\/www.cancerresearch.org\/?post_type=cri_scientists&#038;p=36867"},"modified":"2025-12-12T18:12:42","modified_gmt":"2025-12-12T23:12:42","slug":"ron-gejman-md-phd","status":"publish","type":"cri_scientists","link":"https:\/\/www.cancerresearch.org\/es\/cri-funded-scientists\/ron-gejman-md-phd","title":{"rendered":"Ron Gejman, MD, PhD"},"content":{"rendered":"\n<p>Organ transplant recipients must take lifelong immunosuppressive drugs to prevent rejection of their transplanted organ. While lifesaving, these drugs weaken the immune system and make patients highly vulnerable to aggressive cancers, such as skin cancers. Unfortunately, the most effective modern cancer treatments\u2014immunotherapies that activate the body\u2019s immune cells\u2014are too risky for transplant patients because they can trigger rejection of the donor organ. Dr. Ron Gejman\u2019s research aims to solve this dilemma by developing a new type of personalized immune-based therapy that can safely target cancer in transplant recipients without endangering their transplant.<\/p>\n\n\n\n<p>His approach involves collecting a patient\u2019s own T cells, reprogramming them in the laboratory so that they resist immunosuppressive drugs, and then returning them to the patient to attack cancer cells. Using advanced base-editing technology, Dr. Gejman will modify key genes to make these T cells both drug-resistant and tumor-specific. He is also developing laboratory models using cells from transplant patients with skin cancer to test how these engineered immune cells function in realistic conditions. Together, these efforts aim to create the first T cell therapies designed specifically for immunosuppressed patients.<\/p>\n\n\n\n<p>Dr. Gejman is a physician-scientist with deep expertise in immunology, oncology, and genetic engineering. His earlier research led to a widely used platform for mapping T cell reactivity and revealed how tumor diversity limits immune attack. Building on this foundation, his current work could transform care for transplant recipients by enabling safe, precision-engineered T cell therapies\u2014offering powerful new options where none currently exist.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Sponsor<\/h2>\n\n\n\n<p><strong>Benjamin Izar, MD, PhD<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Projects and Grants<\/h2>\n\n\n\n<p><strong>Precision Base-Edited T Cell Therapy in Transplant Recipients with Cutaneous Squamous Cell Carcinoma<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Organ transplant recipients must take lifelong immunosuppressive drugs to prevent rejection of their transplanted organ. While lifesaving, these drugs weaken the immune system and make patients highly vulnerable to aggressive cancers, such [&hellip;]<\/p>\n","protected":false},"featured_media":36823,"template":"","tax_cancer_type":[455],"tax_grant_type":[486],"tax_award_year":[742],"tax_institutions":[623],"tax_location_states":[494],"class_list":["post-36867","cri_scientists","type-cri_scientists","status-publish","has-post-thumbnail","hentry"],"acf":{"scientist_subhead":"CRI Irvington Postdoctoral Fellow","quote":"","scientist_last_name":"Gejman","show_on_landing":true,"scientist_publish_until":"20281213"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ron Gejman, MD, PhD - Cancer Research Institute<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ron Gejman, MD, PhD - Cancer Research Institute\" \/>\n<meta property=\"og:description\" content=\"Organ transplant recipients must take lifelong immunosuppressive drugs to prevent rejection of their transplanted organ. While lifesaving, these drugs weaken the immune system and make patients highly vulnerable to aggressive cancers, such [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-12T23:12:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/12\/ron-gejman-800x800-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd\",\"url\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd\",\"name\":\"Ron Gejman, MD, PhD - Cancer Research Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/12\/ron-gejman-800x800-1.webp\",\"datePublished\":\"2025-12-12T23:12:41+00:00\",\"dateModified\":\"2025-12-12T23:12:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/12\/ron-gejman-800x800-1.webp\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/12\/ron-gejman-800x800-1.webp\",\"width\":800,\"height\":800,\"caption\":\"Ron Gejman\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ron Gejman, MD, PhD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ron Gejman, MD, PhD - Cancer Research Institute","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd","og_locale":"es_ES","og_type":"article","og_title":"Ron Gejman, MD, PhD - Cancer Research Institute","og_description":"Organ transplant recipients must take lifelong immunosuppressive drugs to prevent rejection of their transplanted organ. While lifesaving, these drugs weaken the immune system and make patients highly vulnerable to aggressive cancers, such [&hellip;]","og_url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd","og_site_name":"Cancer Research Institute","article_modified_time":"2025-12-12T23:12:42+00:00","og_image":[{"width":800,"height":800,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/12\/ron-gejman-800x800-1.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd","url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd","name":"Ron Gejman, MD, PhD - Cancer Research Institute","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/12\/ron-gejman-800x800-1.webp","datePublished":"2025-12-12T23:12:41+00:00","dateModified":"2025-12-12T23:12:42+00:00","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/12\/ron-gejman-800x800-1.webp","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/12\/ron-gejman-800x800-1.webp","width":800,"height":800,"caption":"Ron Gejman"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/ron-gejman-md-phd#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Ron Gejman, MD, PhD"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"fimg_url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/12\/ron-gejman-800x800-1.webp","_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists\/36867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_scientists"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/36823"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=36867"}],"wp:term":[{"taxonomy":"tax_cancer_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_cancer_type?post=36867"},{"taxonomy":"tax_grant_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_grant_type?post=36867"},{"taxonomy":"tax_award_year","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_award_year?post=36867"},{"taxonomy":"tax_institutions","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_institutions?post=36867"},{"taxonomy":"tax_location_states","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_location_states?post=36867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}